News
Since the approval of Luxturna, there has been a wave of gene therapies advancing in clinical trials to treat genetic vision ...
The Scottish Medicines Consortium (SMC) has accepted Outlook Therapeutics’ Lytenava to treat wet age-related macular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results